Innovent Presents P-II Study (CIBI375A201) Results of Pemazyre (pemigatinib) for Advanced Cholangiocarcinoma at AACR 2023
Shots:
- The P-II study evaluates pemigatinib in Chinese patients with unresectable, advanced/recurrent, or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. The trial enrolled 31 patients who received pemigatinib (13.5mg, qd) for 2wks. on/1wk. off schedule
- At the data cutoff date of Dec 2022, the median follow-up was 25.6mos. in 30 efficacy evaluable patients (1 excl. due to inadequate FGFR2 aberrant frequency), m-OS (23.9mos.) with 53.3% OS events, estimated OS rates @12/18/24mos. (73.3%/66.5%/41.4%), respectively with no significant differences in safety outcomes
- Pemazyre was approved & marketed by Innovent in Mainland China, Hongkong & Taiwan for adults with LA or metastatic CCA with a FGFR2 fusion or rearrangement & was also approved in the US for r/r MLNs
Ref: incyte | Image: incyte
Related News:- Incyte’s Pemazyre (pemigatinib) Receives MHLW Approval for Myeloid/Lymphoid Neoplasms
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
